TDP43 Protein Links Neurodegeneration, Cancer & DNA Repair

A protein linked to the devastating neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and dementia has been found to play a surprising role in regulating how cells repair DNA, potentially connecting these conditions to cancer development. Researchers at Houston Methodist have discovered that the protein, known as TDP43, influences the efficiency of DNA mismatch repair – a critical process that corrects errors made when cells copy their genetic material. The findings, published in Nucleic Acids Research, suggest a complex interplay between neurodegeneration, genomic stability, and cancer risk.

For those unfamiliar, DNA mismatch repair is essentially a cellular proofreading system. When DNA is copied, mistakes can happen. This system identifies and corrects those errors, preventing mutations that could lead to disease. TDP43, previously known for its involvement in RNA processing within neurons, appears to act as a regulator of this repair machinery. The study reveals that when TDP43 levels are either too low or too high, the DNA mismatch repair system becomes overactive. Even as seemingly beneficial, this heightened activity can actually destabilize the genome and potentially harm neurons, creating a pathway to both neurological disorders and cancer.

TDP43: Beyond Neurodegeneration

“DNA repair is one of the most fundamental processes in biology,” explains lead investigator Muralidhar L. Hegde, Ph.D., professor of neurosurgery at the Houston Methodist Research Institute’s Center for Neuroregeneration. “What we found is that TDP43 is not just another RNA-binding protein involved in splicing, but a critical regulator of mismatch repair machinery. That has major implications for diseases like ALS and frontotemporal dementia (FTD) where this protein goes awry.” ALS and FTD are characterized by the abnormal accumulation or depletion of TDP43 in the brain, leading to neuronal dysfunction and eventual cell death. This new research suggests that the disruption of DNA repair mechanisms may be a key component of these diseases.

The connection to cancer emerged when researchers analyzed large cancer databases. They observed a correlation between higher levels of TDP43 and a greater number of mutations within tumors. This suggests that the protein’s dysregulation could contribute to genomic instability, a hallmark of cancer. SciTechDaily reports on this finding, highlighting the potential for TDP43 to be a common thread linking seemingly disparate diseases.

Implications for Cancer Mutation Rates

The researchers’ findings suggest a mechanism by which TDP43 could influence cancer development. Normally, DNA mismatch repair helps maintain genomic integrity. However, when TDP43 levels are imbalanced, the system becomes hyperactive, potentially introducing errors during the repair process itself. This could lead to an increased mutation load within cells, driving tumor formation and progression. It’s important to note that this is a correlation observed in database analysis; further research is needed to establish a direct causal link.

“This tells us that the biology of this protein is broader than just ALS or FTD,” Hegde said. “In cancers, this protein appears to be upregulated and linked to increased mutation load. That puts it at the intersection of two of the most important disease categories of our time: neurodegeneration and cancer.”

Reversing Cellular Damage in the Lab

The study also offered a glimmer of hope for potential therapeutic interventions. In laboratory models, reducing the excessive DNA repair activity caused by abnormal TDP43 levels partially reversed cellular damage. This suggests that modulating DNA mismatch repair could be a viable therapeutic strategy for both neurodegenerative diseases and cancer. However, it’s crucial to emphasize that these findings are preliminary and require further investigation in more complex models and, eventually, in human clinical trials.

Understanding TDP43 and its Role

TDP43 is a protein that normally resides in the nucleus of cells, where it plays a role in regulating gene expression. It’s particularly abundant in neurons. In ALS and FTD, TDP43 mislocalizes from the nucleus to the cytoplasm, forming abnormal aggregates that disrupt cellular function. The precise mechanisms underlying this mislocalization and aggregation are still being investigated, but the new research suggests that dysregulation of DNA repair may be a contributing factor. ScienceDaily provides further details on the protein’s function and its connection to these diseases.

What’s Next: Refining Therapeutic Strategies

The Houston Methodist team, along with collaborators from MD Anderson Cancer Center, University of Massachusetts, UT Southwestern Medical Center, and Binghamton University, are now focused on further elucidating the precise mechanisms by which TDP43 regulates DNA mismatch repair. They are also exploring potential therapeutic strategies to modulate TDP43 activity and restore normal DNA repair function. Future research will likely involve developing small molecule inhibitors that can selectively target TDP43 or its downstream effectors. Studies are needed to identify biomarkers that can predict which patients are most likely to benefit from these therapies. The research was supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging of the National Institutes of Health (NIH), as well as funding from the Sherman Foundation Parkinson’s Disease Research Challenge Fund and internal resources at Houston Methodist.

The discovery of TDP43’s role in DNA repair represents a significant step forward in our understanding of the complex interplay between neurodegeneration and cancer. While much work remains to be done, these findings offer a promising new avenue for developing targeted therapies for these devastating diseases.